ニュートンバイオキャピタルは
第1号ファンドのクロージングを
出資金総額113M超ユーロで完了しました

     

慢性疾患に対する
新たなソリューションを育む
ライフサイエンス
ベンチャー・キャピタル

get in touch

私たちが
投資するもの

ニュートン バイオキャピタルのアプローチは、ヨーロッパ大陸の主要国及び日本の有望なアーリーステージのプロジェクトや、有望な技術が存在していながら顧みられない、あるいは過小評価されているレイトステージのプロジェクトの中から価値を発掘し、サポートすることです。

ニュートン バイオキャピタルは、慢性疾患の予防と治療のためのソリューションを開発したいというビジョンを描く治療法、診断技術、医療機器、臨床栄養学、デジタルバイオテクノロジー企業に投資をします。

our scope

いかにして価値を生み出すか?


情熱的なベンチャーの起業家と力を合わせ、臨床での可能性や市場価値を実証できるような確固たるコンセプトの証明につながるビジネス戦略を策定し、それを実行します。

ニュートン バイオキャピタルの大陸横断的アプローチは、2つの重要なライフサイエンスの市場を結びつけ、さらに(1)重要な企業ネットワーク、(2)大規模な経営人材のプール、(3)幅広いサイエンスのコミュニティ、そして(4)異なる資本市場へのより良いアクセスを可能にします。

our investment approach

チームメンバー


ヘルスケア業界において長年の経験を有するメンバーと、経験豊富なベンチャーキャピタリストが集結したことで、戦略的な洞察を活用し、患者と投資家の両方にとって有益な価値を生み出すことができます。

meet the team

Latest news

9月, 19th

Sequana Medical appoints leading experts as Heart Failure Scientific Advisors

Dr. Butler, Dr. Costanzo, Dr. Tang and Dr. Testani to advise on alfapump® DSR development

read more
6月, 4th

Sequana Medical announces unconditional IDE approval from U.S. FDA to start alfapump® pivotal study (POSEIDON)

read more
5月, 15th

SEQUANA MEDICAL announces inclusion of alfapump® in German treatment guidelines (DGVS) for complications of liver cirrhosis

Sequana Medical announces inclusion of alfapump® in German treatment guidelines (DGVS) for complications of liver cirrhosis Further validation builds on U.S. FDA1 Breakthrough Device status and inclusion in U.K. NICE2 recommendations and EASL3 guidelines Ghent, BELGIUM – 15 May 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces that the alfapump has been included in the DGVS (“German Society of Gastroenterology Digestive and Metabolic Diseases”) guidelines for complications of liver cirrhosis. These guidelines provide evidence-based key recommendations for diagnosis and therapy of complications of liver cirrhosis and upgrade the 2011 version. An interdisciplinary team of medical experts and patient support groups developed the guidelines following the recommendations by the Association of Scientific Medical Societies for evidence-based consensus guidelines. Sequana Medical’s alfapump is currently commercialised in Europe for the treatment of refractory liver ascites, which is a key complication of liver cirrhosis with limited treatment options and severely impacting patients’ quality of life. The potential of the alfapump to address this unmet medical need has been demonstrated in multiple clinical studies showing a significant reduction in the need for large volume paracentesis (LVP), the current standard of care, and a significant improvement in patients’ quality of life. The DGVS guidelines position the alfapump as a good and safe alternative to repeated LVP and states that the alfapump may also be considered in patients contraindicated for use of a transjugular intrahepatic portosystemic shunt (TIPS). There are numerous complications with TIPS, including hepatic encephalopathy and heart failure. Reference is made to the improvement in clinical outcomes through extensive clinical experience with the alfapump, as well as to the improvement in patient’s quality of life and nutritional benefit demonstrated in clinical studies. Prof. Dr. Thomas Berg, Head of Hepatology at the University of Leipzig, commented: “I welcome the inclusion of the alfapump in the DGVS guidelines which are considered the reference treatment guidelines in Germany for patients suffering from complications of liver cirrhosis. There is a clear need for treatment alternatives for this underserved patient group. The increasing body of clinical evidence and real-world experience demonstrate the benefits of using the alfapump when performed in experienced centres and well-selected patients with refractory liver ascites.” Ian Crosbie, Chief Executive Officer at Sequana Medical, added: “The inclusion of the alfapump in the DGVS guidelines is further proof of the increasing independent support and acceptance for alfapump use. We look forward to starting our North American POSEIDON pivotal study in recurrent or refractory liver ascites, expected in the second half of 2019, to support approval of the alfapump in the U.S. and Canada. The forecast 1 Food and Drug Administration 2 The National Institute for Health and Care Excellence 3 European Association for the Study of the Liver PRESS RELEASE growth in cirrhosis and refractory ascites as a result of non-alcoholic steatohepatitis (NASH) is a key health concern in the U.S. and makes the need for a modern and convenient treatment option all the more important.” For more information, please contact: Sequana Medical Lies Vanneste Director IR Tel: +32 (0) 498 05 35 79 Email: IR@sequanamedical.com Consilium Strategic Communications Amber Fennell, Sukaina Virji, Melissa Gardiner Tel: +44 (0) 203 709 5000 Email: sequanamedical@consilium-comms.com About Sequana Medical Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical's technology is based on its proprietary alfapump® platform, a fully implantable, programmable, wirelessly-charged, battery-powered system for automatic and continuous removal of fluid from the abdomen, which is applicable across multiple life-threatening disorders. The alfapump is being commercialised in Europe for the management of refractory ascites (chronic fluid build-up in the abdomen) due to liver cirrhosis and malignant ascites. The number of patients with refractory liver ascites is forecast to increase dramatically due to the growing prevalence of NASH (Non-alcoholic Steatohepatitis). Over 700 alfapump systems have been implanted to date and since April 2018, the alfapump has been included in the EASL (European Association for the Study of the Liver) clinical practice guidelines for decompensated cirrhosis. In January 2019, the FDA has granted Breakthrough Device designation for the alfapump for the treatment of recurrent or refractory liver ascites. The alfapump has not yet received regulatory approval in the U.S. and Canada and the Company expects to start POSEIDON, the North American pivotal study in in the second half of 2019 to support approval of the alfapump in recurrent or refractory liver ascites. The alfapump is one of the first safe and effective, long-term alternatives to large-volume paracentesis (LVP) for the management of ascites, offering major advantages to patients, clinicians and healthcare systems. By automatically and continuously moving ascites to the bladder, where the body eliminates it naturally through urination, the alfapump prevents fluid build-up and its possible complications, improving patient quality of life and nutrition, and potentially reducing hospital visits and healthcare costs. The alfapump DirectLink technology allows clinicians to receive pump performance information and more effectively manage patients treated by the alfapump. Sequana Medical has leveraged its alfapump experience and is developing alfapump DSR to deliver a convenient and fully implanted system for DSR therapy, its novel and proprietary approach for the management of volume overload in heart failure. Data from animal studies presented at EuroPCR 2018 and HFSA 2018 indicate that DSR therapy is effective and safe. The first-in-human single dose DSR proof-of-concept study has been conducted by Dr. Testani at Yale University in the U.S. and results are scheduled to be presented PRESS RELEASE at Heart Failure 2019 on 27 May 2019. The repeated dose DSR proof-of-concept study is expected to start in the second half of 2019. Sequana Medical is headquartered in Ghent, Belgium.For further information, please visit www.sequanamedical.com. Important Regulatory Disclaimers Any statement in this press release about safety and efficacy of the alfapump does not apply to the U.S. and Canada because the device is currently undergoing clinical investigation in these territories. DSR therapy is still in development and it should be noted that any statements in this press release regarding safety and efficacy arise from pre-clinical studies and ongoing clinical investigations which have yet to be completed. There is no link between DSR therapy and ongoing investigations with the alfapump system in Europe, the U.S. and Canada. Forward-looking statements This press release may contain predictions, estimates or other information that might be considered forward- looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

read more